Go to content

Publications

467 publications

Enter search criteria
Fill in keyword(s) to narrow your search.
Period
You can select a specific type of a publication you are looking for, such as press releases or speeches
Sort by:

  1. GVS advice CGRP inhibitors erenumab, fremanezumab, galcanezumab (Aimovig®, AJOVY®, Emgality®) for the treatment of patients with episodic and chronic migraine

    The National Health Care Institute has completed its assessment (using the CBG-ZIN parallel procedure) whether roxadustat ...

    Report | 17-09-2021

  2. GVS advice roxadustat (Evrenzo®) for the treatment of symptomatic anaemia in chronic kidney damage

    The National Health Care Institute has completed its assessment (using the CBG-ZIN parallel procedure) whether roxadustat ...

    Report | 03-09-2021

  3. GVS advice drospirenon-estetrol (Drovelis®)

    The National Health Care Institute has completed its assessment whether drospirenon/estetrol (Drovelis®) is interchangeable with ...

    Report | 31-08-2021

  4. Follow-up advice on conditional inclusion of larotrectinib (Vitrakvi®)

    Zorginstituut Nederland recommends that larotrectinib (Vitrakvi®) should be conditionally included in the basic health care ...

    Report | 16-08-2021

  5. Follow-up advice on conditional inclusion of entrectinib (Rozlytrek®)

    Zorginstituut Nederland recommends that entrectinib (Rozlytrek®) should be conditionally included in the basic health care ...

    Report | 16-08-2021

  6. Package advice ipilimumab (Yervoy®) in combination with nivolumab (Opdivo®)

    The National Health Care Institute has completed its assessment whether ipilimumab (Yervoy®) in combination with nivolumab ...

    Report | 11-08-2021

  7. GVS advice on the reassessment of tafamidis (Vyndaqel®)

    The Zorginstituut recommends not to include tafamidis (Vyndaqel®) in the GVS, unless a price reduction of at least 50% can be ...

    Report | 11-08-2021

  8. Advice on the reassessment of axicabtagene ciloleucel (Yescarta®)

    The National Health Care Institute has carried out the reassessment of axicabtagene ciloleucel (Yescarta®).

    Report | 26-07-2021

  9. GVS advice on ferrimaltol (Feraccru®) for treating iron deficiency

    Zorginstituut Nederland recommends that ferrimaltol (Feraccru®) should not be included in the Medicine Reimbursement System ...

    Report | 26-07-2021

  10. GVS advice on subcutaneous buprenorphine (Buvidal®)

    Zorginstituut Nederland has completed its assessment whether the product subcutaneous buprenorphine (Buvidal®) is interchangeable ...

    Report | 21-07-2021

Go to